Somewhat Positive Media Coverage Somewhat Unlikely to Impact Antares Pharma (ATRS) Stock Price

Press coverage about Antares Pharma (NASDAQ:ATRS) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Antares Pharma earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 47.4104307766881 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

Several equities research analysts recently issued reports on ATRS shares. BidaskClub raised Antares Pharma from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Antares Pharma in a research note on Thursday, February 15th. Finally, ValuEngine raised Antares Pharma from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $3.94.

Shares of ATRS stock opened at $2.20 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.94 and a current ratio of 3.53. Antares Pharma has a 52 week low of $1.58 and a 52 week high of $4.09. The stock has a market capitalization of $351.21, a PE ratio of -22.00 and a beta of 0.23.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Tuesday, March 13th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. Antares Pharma had a negative return on equity of 44.29% and a negative net margin of 30.71%. The firm had revenue of $14.00 million during the quarter, compared to analyst estimates of $15.44 million. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. sell-side analysts forecast that Antares Pharma will post -0.08 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Antares Pharma (ATRS) Stock Price” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3296234/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-antares-pharma-atrs-stock-price.html.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Insider Buying and Selling by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

IHI  & Intevac  Financial Comparison
IHI & Intevac Financial Comparison
Contrasting Jamba Juice  and Dunkin’ Brands
Contrasting Jamba Juice and Dunkin’ Brands
Hudson’s Bay  Receives Consensus Rating of “Hold” from Analysts
Hudson’s Bay Receives Consensus Rating of “Hold” from Analysts
TUI Group  Receives Consensus Recommendation of “Buy” from Analysts
TUI Group Receives Consensus Recommendation of “Buy” from Analysts
Premier Oil  Given Average Rating of “Hold” by Brokerages
Premier Oil Given Average Rating of “Hold” by Brokerages
Axovant Sciences  Getting Somewhat Positive Press Coverage, Study Finds
Axovant Sciences Getting Somewhat Positive Press Coverage, Study Finds


© 2006-2018 Ticker Report. Google+.